Mealey's (September 15, 2015, 12:02 PM EDT) -- SAN DIEGO — The California federal judge overseeing the incretin mimetic multidistrict litigation on Sept. 11 ordered the return of inadvertently disclosed data from defendant Novo Nordisk Inc.’s LEADER clinical trial, saying it should be protected until the study is completed and published (In Re: Incretin-Based Therapies Products Liability Litigation, MDL Docket No. 2452, No. 13-md-2452, S.D. Calif.).

(LEADER study order available. Document #28-150917-008R.)

During discovery, Novo Nordisk inadvertently disclosed a portion of unblended data from the pending and incomplete LEADER cardiovascular trial. Novo Nordisk subsequently...